Abstract. Death-associated protein kinase (DAPK) is a serine/threonine kinase that participates in the modulation of apoptosis and tumor suppression. Our previous study revealed high levels of DAPK protein expression in differentiated endometrial adenocarcinoma cells. To clarify the role of DAPK in human endometrial adenocarcinomas, we downregulated endogenous DAPK expression in HHUA cells, a well-differentiated endometrial adenocarcinoma cell line, using specific small-interfering RNAs (siRNAs). The suppression of endogenous DAPK expression triggered apoptosis in HHUA cells, as evidenced by an increase in the sub-G1 DNA content in flow cytometric analyses. The apoptosis induced by the DAPK siRNA transfections was caspase-dependent, as characterized by the activations of caspase-3, -8 and -9. RNase protection assays detected higher levels of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), DR4 and DR5 transcripts in the DAPK siRNA-transfected HHUA cells than in the control siRNA-transfected cells. Consistent with these findings, enzyme-linked immunosorbent assays revealed that the DAPK siRNA transfections significantly increased the secretion of TRAIL protein from the cells. Treatment with recombinant human TRAIL protein dose-dependently suppressed the cell viability of HHUA cells. The present findings reveal that down-regulation of endogenous DAPK expression in HHUA cells induces caspasedependent apoptosis, possibly through increased TRAIL, DR4 and DR5 signaling, thereby suggesting that DAPK expression is essential for HHUA cell survival. Consequently, endogenous DAPK mRNA may represent a potential candidate for molecularly targeted anticancer therapies.
Introduction
Endometrial adenocarcinomas are the most common gynecological malignancies. The development of these cancers results from a series of genetic alterations that transform the normal endometrium through hyperplasia and dysplasia to culminate in overt carcinoma. The first-line treatment for patients with early endometrial cancers is radical surgical resection. For advanced endometrial cancers, radiotherapy and/or chemotherapy are usually combined with the surgical treatment. Chemotherapy is applied at first for unresectable advanced endometrial cancer patients and after surgery, radiotherapy or chemotherapy for recurrent endometrial cancer patients. However, when patients have been treated with repeated chemotherapy regimens, their cancer cells can become multidrug-resistant to typical anticancer drugs. Such multidrug-resistant endometrial cancer patients require novel molecularly targeted anticancer therapies to induce specific cell death in endometrial cancer tissues. The targeted molecules must be important survival factors for endometrial adenocarcinoma cells but not essential factors for individual human survival. However, there have been no reports of the identification of molecules that can cause specific endometrial adenocarcinoma cell death and that do not induce any severe adverse effects in humans.
Apoptosis is crucial for embryonic development and maintenance of tissue homeostasis. The signaling pathways leading to apoptosis are comprised of both extrinsic and intrinsic pathways. The extrinsic pathway involves the engagement of members of the tumor necrosis factor receptor (TNFR) family, also known as the death receptor family. These receptors bind to their specific ligands and recruit Fas-associated death domain (FADD) and procaspase-8 to assemble the death-inducing signaling complex (DISC), thereby resulting in the activation of caspases, including caspase-3 and -8, which induce apoptosis (1) . Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a member of the TNF family (2, 3) . Similar to the well-documented interplay between Fas ligand and Fas that activates caspase-8 to directly elicit apoptosis, TRAIL binds to its specific death receptors, DR4 and DR5, to induce apoptosis, while the expressions of its decoy receptors, DcR1 and DcR2, antagonize (4) (5) (6) (7) . In addition, TRAIL appears to be selectively cytotoxic toward tumor cells without exhibiting appreciable cytotoxicity toward normal cells (8) (9) (10) (11) (12) . The intrinsic pathway of apoptosis is triggered in response to chemotherapeutic drugs, and involves the formation of apoptosomes composed of cytochrome c released from mitochondria as well as apoptotic protease-activating factor-1 (Apaf-1) and procaspase-9, in which caspase-9 is cleaved to further promote the activation of caspase-3 that leads to apoptosis (13) . Recent reports have also shown that active caspase-8 has the ability to process the proapoptotic Bcl-2 family member Bcl-2-interacting domain (BID) to truncated BID (tBID) to further promote cytochrome c release, thereby linking the extrinsic pathway to the intrinsic pathway (14, 15) . Death-associated protein kinase (DAPK) is a Ca 2+ / calmodulin-dependent serine/threonine kinase that functions as a positive mediator of apoptosis triggered by interferon (IFN)-Á, TNF-·, anti-Fas antibodies, transforming growth factor-ß, c-myc and E2F oncogenes, ceramide and detachment from the extracellular matrix (16) (17) (18) (19) (20) (21) (22) (23) . Moreover, loss of DAPK expression has been implicated in tumorigenesis and metastasis (24, 25) , thus suggesting a crucial role for DAPK in the apoptotic process under pathological conditions. On the other hand, several lines of evidence have indicated that DAPK may have an antiapoptotic function. Inhibition of DAPK expression in HeLa cells, 3T3 fibroblasts and primary human vascular smooth muscle cells with an antisense DAPK was found to increase apoptosis (26, 27) . These studies support the notion that DAPK plays cytoprotective roles under certain cell survival conditions.
In a previous study, we detected higher DAPK protein expression levels in differentiated endometrial adenocarcinoma cells than in normal primary endometrial cells and several ovarian and uterine carcinoma cells including HeLa cells (28) . These results suggest that DAPK regulates cell survival or apoptosis of human endometrial adenocarcinoma cells. When we bred DAPK-mutant mice for several years to investigate their nervous systems and ovarian functions, we observed that the DAPK-mutant mice showed similar survival rates to normal adult mice and became pregnant and had offspring (unpublished data). Taken together, these results suggest that DAPK is neither a lethal molecule for an individual nor an essential molecule for reproduction. Therefore, we examined whether DAPK represents a candidate molecule for a targeted anticancer therapy for advanced cancer patients with differentiated human endometrial adenocarcinoma in which DAPK protein is highly expressed. To achieve this, we utilized specific DAPK small-interfering RNAs (siRNAs) to knock down endogenous DAPK expression in HHUA cells (29) to directly investigate the role of endogenous DAPK in endometrial adenocarcinoma cell survival.
Materials and methods
Cell line and culture. The HHUA cell line (29) was obtained from Riken Cell Bank (Tsukuba, Japan). The cells were cultured in OPTI-MEM (Invitrogen Corp., Carlsbad, CA) supplemented with 5% fetal bovine serum (FBS) (Equitech Bio Inc., Ingram, TX), penicillin (100 U/ml), streptomycin (100 U/ml) and Fungizone (0.25 μg/ml; Invitrogen Corp.) in the presence of 5% CO 2 and 95% air at 37˚C.
Transfection of DAPK siRNAs. Two DAPK siRNA duplexes were designed and synthesized by iGENE Therapeutics Inc. (Tsukuba, Japan). The siRNA sequences are shown in Table I . A negative control siRNA was purchased from Ambion Inc. (Austin, TX). Lipofectamine 2000 (Invitrogen Corp.) was used as the transfection reagent according to the manufacturer's instructions. For experiments, cells were seeded in 6-well plates (2.5x10 5 cells/well) or 10-cm dishes (2x10 6 cells/dish), cultured for 24 h and then transfected with the DAPK siRNAs or control siRNA at a final concentration of 50 nM. Subsequently, the cells were cultured for 24-48 h for mRNA analyses and 48-72 h for protein assays before being harvested as indicated.
RNA isolation and real-time RT-PCR.
Total RNA was isolated from the cultured cells using an RNeasy Mini kit (Qiagen Inc., Valencia, CA) for real-time RT-PCR and RNase protection assays. For real-time RT-PCR, 1 μg of total RNA was predigested with DNase I (Invitrogen Corp.) and subjected to cDNA synthesis using a reverse transcriptase kit (Bio-Rad, Hercules, CA) in a 20-μl reaction mixture. The cDNA product was diluted to 100 μl. Real-time PCR amplifications were performed using an iCycler (Bio-Rad). Each PCR mixture (25 μl) contained 2.5 μl of diluted cDNA, 12.5 μl of iQ™ SYBR Green Supermix (Bio-Rad) and 0.5 μM primers. The PCR amplifications were performed with specific primers for DAPK (forward, 5'-GATAGAAATGTCCCCAAACC TCG-3'; reverse, 5'-TCTTCTTGGATCCTTGACCAGAA-3') to amplify a 343-bp product. Actin was amplified as a positive control. For each analysis, an initial hot start at 95˚C for 3 min was followed by 40 cycles of amplification (95˚C for 30 sec, 55˚C for 30 sec and 72˚C for 60 sec). The DAPK mRNA levels in the DAPK siRNA-treated cells relative to the control siRNA-transfected cells were calculated based on the Table I . DAPK siRNA sequences. Caspase activity assay. The caspase-3/7, -8 and -9 activities in the DAPK siRNA-treated or control siRNA-transfected HHUA cells were measured using Caspase-Glo™-3/7, -8 and -9 Assay kits (Promega Corp., Madison, WI) according to the manufacturer's instructions with some previously described modifications (1). Both adherent and floating cells were collected and lysed in phosphate-buffered saline containing 1% NP-40, 0.1% sodium dodecyl sulfate, complete protease inhibitor cocktail and 1 mM phenylmethyl sulfonyl fluoride. After centrifugation, 10 or 20 μg of protein in a total volume of 50 μl was mixed with 50 μl of equilibrated CaspaseGlo™-3/7, -8 or -9 reagent and incubated for 1 h at room temperature. Subsequently, the luminescence was measured using a BLR-301 Luminescence Reader (Aloka Corp., Tokyo, Japan). The caspase activities were calculated based on standard curves generated using human recombinant caspase-3, -8 and -9 (Biomol Research Laboratories Inc., Plymouth Meeting, PA), respectively.
Cell viability assay. Ribonuclease protection assay. A multiprobe RNase protection assay was performed using a RiboQuant™ hAPO-3d multiprobe template set and an RNase protection assay (RPA) kit (BD PharMingen) according to the manufacturer's protocol. Biotin-conjugated probes were prepared using a Non-Rad In Vitro Transcription kit (BD PharMingen). The probes were combined with 10 μg of total RNA isolated from DAPK siRNA-transfected or control siRNA-transfected HHUA cells. After denaturation at 95˚C for 3 min, the mixtures were hybridized at 56˚C for 12-16 h before RNase digestion. RNA hybrids were separated in 4.75% acrylamide/8 M urea denaturing gels, and the protected fragments were transferred to positively charged nylon membranes. The fragments on the membranes were detected using the RPA detection kit and the protected fragments were quantified with a luminocapture apparatus and lane analyzer software (ATTO Corp.). The relative expression of each mRNA species was calculated after normalization by the expression level of the housekeeping gene L32.
Enzyme-linked immunosorbent assay (ELISA) of TRAIL.
DAPK siRNA-transfected or control siRNA-transfected HHUA cells were collected at various time-points and lysed in lysis buffer containing a protease inhibitor provided in a Function ELISA™ TRAIL/Apo2L kit (Active Motif, Carlsbad, CA). The TRAIL assay was performed according to the manufacturer's instructions. Briefly, 100 μg of cell lysates or standard recombinant TRAIL at known concentrations were added to wells coated with a capture antibody specific for TRAIL and incubated for 4 h. After washing, a detection antibody was added to the wells and incubated for 60 min. After further washing, an alkaline phosphatase (ALP)-conjugated secondary antibody was added to the wells and incubated for 60 min. After five washes, a substrate solution for ALP was added to induce the formation of a colored reaction product. The intensities of the colored product in the wells were determined by measuring the absorbances at 405 nm using a spectrophotometer.
Statistical analysis. The data are expressed as means ± SD. Comparisons between experimental groups were performed by analysis of variance (ANOVA). If the ANOVA was significant, post-hoc comparisons were conducted using Scheffe's test. The level of statistical significance was set at p<0.05.
Results

Specific down-regulation of endogenous DAPK expression by DAPK siRNA transfections induces apoptosis in HHUA cells.
We previously reported that endogenous DAPK protein was highly expressed in the well-differentiated endometrial INTERNATIONAL JOURNAL OF ONCOLOGY 37: [203] [204] [205] [206] [207] [208] [209] [210] 2010 adenocarcinoma cell line HHUA compared with normal endometrial tissues. To investigate the role of endogenous DAPK protein in HHUA cells, we performed siRNA transfection experiments using two double-stranded siRNAs (DAPK siRNAs 001 and 002) against human DAPK mRNA to examine the effects of specific down-regulation of DAPK expression in HHUA cells. Real-time RT-PCR analyses confirmed that transient transfections of the DAPK siRNA sequences into HHUA cells significantly decreased the DAPK mRNA expression levels by ~75% after 24 h relative to the levels in the control siRNA-transfected cells (Fig. 1A) . Similarly, Western blot analyses revealed that DAPK protein expression was strongly suppressed in DAPK siRNAtransfected HHUA cells at 48 h after transfection (Fig. 1B) . No non-specific inhibitory effects were detected for ß-actin protein expression as an internal control.
Next, we examined the DAPK siRNA-transfected and control siRNA-transfected HHUA cells for the effects of the reduced endogenous DAPK expression. Many of the DAPK siRNA-transfected cells became detached from the substratum, whereas the control siRNA-transfected cells did not (Fig. 2) , suggesting that reduced DAPK expression led to reduced cell adhesion and/or cell death induction in HHUA cells. To clarify these possibilities, the sub-G1 DNA contents in the DAPK siRNA-transfected and control siRNA-transfected cells were evaluated by flow cytometric analyses. Significantly higher percentages of sub-G1 DNA contents were detected in the DAPK siRNA-transfected cells compared with the control siRNA-transfected cells (54.1 and 26.23% vs. 5.98%) (Fig. 3) . These data indicate that DAPK siRNAmediated knockdown of endogenous DAPK expression induces cell death in HHUA cells.
DAPK siRNA-induced cell death in HHUA cells is caspasedependent.
It is well documented that apoptosis is mediated by a cascade of caspases, which are further divided into initiators or effectors of apoptosis such as caspase-3, -8 and -9. Therefore, we examined whether procaspase-3, -8 and -9 were activated in HHUA cells after transfection of the DAPK siRNAs. First, we conducted Western blot analyses to examine caspase activation. As shown in Fig. 4 , cleaved fragments of caspase-3, -8 and -9 were strongly enhanced in the DAPK siRNA-treated HHUA cells compared with the control siRNAtreated cells. Next, the DAPK siRNA-treated and control siRNA-treated cells were subjected to comparative caspase activity assays. Consistent with the results of the Western blot analyses, the DAPK siRNA-treated cells showed much higher levels of caspase-3, -8 and -9 activities than the control siRNA-transfected cells (Fig. 5) . Taken together, these data indicate that knockdown of endogenous DAPK by DAPKspecific siRNAs triggers caspase-dependent apoptosis in HHUA cells. Alternatively, DAPK may be an essential molecule for maintaining the cell survival of HHUA cells. the mechanism underlying the apoptosis induced by DAPK knockdown, we performed RNase protection assays of apoptosis-related genes in HHUA cells transfected with the DAPK siRNAs or control siRNA. As shown in Fig. 6 , DAPK siRNA transfections increased the mRNA levels of death receptor-mediated signaling molecules such as Fas, DcR1, DR5, DR4 and TRAIL in the DAPK siRNA-transfected HHUA cell. Of note, the expression levels of the death receptor DR4 and DR5 mRNAs and, in particular, TRAIL mRNA were simultaneously and remarkably elevated. In addition, the mRNA expression of an antagonistic decoy receptor, DcR1, was also slightly elevated. In the contrast, despite the increased mRNA expression of Fas, Fas ligand mRNA expression was not detected. (Fig. 7A) . To further verify the possibility that the apoptosis observed in the DAPK siRNAtransfected cells was mediated through a TRAIL-mediated apoptotic signaling pathway, we investigated the susceptibility of HHUA cells to TRAIL. As expected, treatment of HHUA cells with recombinant soluble human TRAIL suppressed the cell viability in a dose-dependent manner (Fig. 7B) , suggesting that HHUA cells express functional TRAIL receptors on their cell surface.
Endogenous DAPK expression in HHUA cells regulates the mRNA expressions of apoptosis-related genes. To elucidate
Discussion
This is the first report to show that DAPK may be a strong candidate molecule for a targeted anticancer therapy for human endometrial adenocarcinoma cells. DAPK is a Ca 2+ / calmodulin-dependent cytoskeleton-localized serine/threonine kinase that functions as a positive or negative mediator of apoptosis triggered by various apoptotic stimuli (16) (17) (18) (19) (20) (21) (22) (23) 26, 27) . To elucidate the role of endogenous DAPK in human endometrial adenocarcinoma cells, we examined the effects of suppression of endogenous DAPK expression after transfection of specific DAPK siRNAs into HHUA cells, which are welldifferentiated endometrial carcinoma cells. HHUA cells were reported to express higher levels of DAPK protein than several ovarian and uterine carcinoma cell lines and the normal human endometrium (28) . The present findings revealed that the suppression of endogenous DAPK expression by the specific DAPK siRNAs induced TRAIL-mediated caspasedependent apoptosis in HHUA cells, indicating an essential role for endogenous DAPK in HHUA cell survival. Taken together, these results suggest that DAPK may represent a potential target for molecularly targeted cancer therapies.
The DAPK siRNA transfections induced remarkable expression of TRAIL mRNA and, to lesser extents, DR4 and DR5 mRNA expressions. The increased expression levels of DR4 and DR5 may have enhanced the apoptotic signals in response to the increased TRAIL expression induced by the DAPK siRNA transfections. We further found that the DAPK siRNA-transfected HHUA cells secreted large amounts of TRAIL protein and that treatment of HHUA cells with recombinant soluble human TRAIL suppressed the cell viability in a dose-dependent manner. Taken together, these data indicate that the suppression of endogenous DAPK expression in the DAPK siRNA-transfected HHUA cells mainly induced apoptosis through a TRAIL-mediated apoptotic signaling pathway in an autocrine fashion. There is a recent report that synergistic cotreatment of tumor cells with TRAIL and chemotherapeutic drugs exerts cytotoxic effects on tumor cells via increased DR5 expression (30) . Therefore, DAPK siRNA transfection could be useful as a combination therapy with anticancer chemotherapy for patients with multidrug-resistant cancers. Accordingly, DAPK may represent a novel candidate molecule for molecularly targeted anticancer therapies for human TRAIL receptor-expressing cancer cells, presumably through activation of the TRAIL-TRAIL receptor signaling pathway.
The targets for molecularly targeted anticancer therapies must have high specificity for the cancer cells. DAPK is highly expressed in differentiated human endometrial adenocarcinoma cells (28) . Moreover, the systemic adverse effects of DAPK siRNA treatment on individuals are thought to be tolerable because DAPK-mutant mice develop into adults in a similar manner to normal mice and can reproduce (unpublished data). Therefore, DAPK may be a powerful candidate molecule for a targeted anticancer therapy for advanced endometrial adenocarcinomas.
